Bain Capital, Mitsubishi tanabe pharma

Bain Capital to Buy Mitsubishi Chemical’s Pharma Business for More Than $3 Billion
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key businesses.
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group Corporation. The investment values the business at approximately $3.3 billion.
Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion
U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group.
Bain to Acquire Mitsubishi Tanabe Pharma in $3.3 Billion Deal
Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group Corp.’s pharmaceutical unit, adding to a dealmaking boom in Japan.
Bain buys 340-year-old pharma company to fast-track Japan’s drug development
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine
Mitsubishi Chemical to sell drug unit to Bain in $3.36 billion deal
Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it seeks to streamline its portfolio.
Bain Capital to buy Mitsubishi Chemical’s pharma unit for $3.3B
Investment firm Bain Capital said on Friday that it has signed an agreement to acquire Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group (OTCPK:MTLHY) for approximately 510 billion JPY (3.3 billion USD).

SelectQuote, Bain Capital

Bain Capital Says It May Withdraw Tender Offer Proposal for Fuji Soft
TOKYO (Reuters) - U.S. private equity firm Bain Capital said it may withdraw its tender offer proposal for Japanese IT firm ...
EconoTimes2h
Bain Capital May Withdraw Fuji Soft Bid as KKR Ups Offer
Bain Capital is considering withdrawing its tender offer for Japanese IT firm Fuji Soft after rival U.S. private equity giant ...
BioSpace17h
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...
M&A News: Bain Capital Buys 350-Year-Old Japanese Drugs Firm for $3.4 billion
Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...
Bisnow3d
Bain Names New Head Of Real Estate Capital Markets
Keith Largay joins Bain Capital from JLL, where he spent 14 years and most recently served as co-head of its Chicago office.
Business Wire5d
Bain Capital Announces Majority Investment in Milacron, a Leading Global Provider of Highly Engineered Plastic Processing Solutions
BOSTON & BATESVILLE, Ind.--(BUSINESS WIRE)--Bain Capital, a leading private investment firm, today announced a majority investment in the Milacron Injection Molding and Extrusion business (or the ...
Bain, Endeavour’s Medical Device Company Kestra Files for IPO
Kestra Medical Technologies Ltd. has filed for an initial public offering, showing revenue growth that nearly tripled.Most ...
Bain Capital drafts in former Insignia Financial boss Renato Mota to boost its takeover tilt
Bain Capital kicked off the bidding war for MLC-owner Insignia Financial and has certainly pulled out all the stops to ...